title: 6-(Het)aryl-7-deazapurine ribonucleosides as novel potent cytostatic agents.
abstract: A series of novel 7-deazapurine ribonucleosides bearing an alkyl, aryl, or hetaryl group in position 6 and H, F, or Cl atom in position 7 has been prepared either by Pd-catalyzed cross-coupling reactions of the corresponding protected 6-chloro-(7-halogenated-)7-deazapurine ribonucleosides with alkyl- or (het)arylorganometallics followed by deprotection, or by single-step aqueous phase cross-coupling reactions of unprotected 6-chloro-(7-halogenated-)7-deazapurine ribonucleosides with (het)arylboronic acids. Significant cytostatic effect was detected with a substantial proportion of the prepared compounds. The most potent were 7-H or 7-F derivatives of 6-furyl- or 6-thienyl-7-deazapurines displaying cytostatic activity in multiple cancer cell lines with a geometric mean of 50% growth inhibition concentration ranging from 16 to 96 nM, a potency comparable to or better than that of the nucleoside analogue clofarabine. Intracellular phosphorylation to mono- and triphosphates and the inhibition of total RNA synthesis was demonstrated in preliminary study of metabolism and mechanism of action studies.
authors.affiliation: Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Gilead Sciences & IOCB Research Center, Flemingovo nam. 2, CZ-16610 Prague 6, Czech Republic.
authors.forename: Petr
authors.initials: P
authors.lastname: Naus
authors.forename: Radek
authors.initials: R
authors.lastname: Pohl
authors.forename: Ivan
authors.initials: I
authors.lastname: Votruba
authors.forename: Petr
authors.initials: P
authors.lastname: Dzubák
authors.forename: Marián
authors.initials: M
authors.lastname: Hajdúch
authors.forename: Ria
authors.initials: R
authors.lastname: Ameral
authors.forename: Gabriel
authors.initials: G
authors.lastname: Birkus
authors.forename: Ting
authors.initials: T
authors.lastname: Wang
authors.forename: Adrian S
authors.initials: AS
authors.lastname: Ray
authors.forename: Richard
authors.initials: R
authors.lastname: Mackman
authors.forename: Tomas
authors.initials: T
authors.lastname: Cihlar
authors.forename: Michal
authors.initials: M
authors.lastname: Hocek
mesh_terms: D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D054697:Cytostatic Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D015394:Molecular Structure; D011687:Purines / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D012263:Ribonucleosides / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D013237:Stereoisomerism; D013329:Structure-Activity Relationship
chemical_list: C512929:7-deazapurine; D000970:Antineoplastic Agents; D054697:Cytostatic Agents; D011687:Purines; D012263:Ribonucleosides